Phase 1 study of the combination of 1018 ISS, irinotecan and cetuximab in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine, oxaliplatin or irinotecan with or without bevacizumab

Trial Profile

Phase 1 study of the combination of 1018 ISS, irinotecan and cetuximab in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine, oxaliplatin or irinotecan with or without bevacizumab

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs 1018-ISS (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 16 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 01 Nov 2007 Status changed from recruiting to in progress.
    • 20 Sep 2007 The expected completion date for this trial is now 1 Mar 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top